Dendreon: Media's Hype and Hope!
by Hisham S. Ayoub, DMD
BioHealth Investor.com
My post on Dendreon (DNDN) a couple of days ago attracted a strong response, both critical and approving.
But I am not surprised at the level of hype the article generated; Dendreon has been a gold mine for financial bloggers and sites for the last few months.
Adam Feuerstein and James Altucher can both attest to the large following their Dendreon posts atract. So can 247WallSt, and so can I.
I follow Adam's writing on a regular basis, and find his analysis both accurate and informative. He has a great outlook on the reality of various investment situations in biotech. But his criticism of the media's pumping of Dendreon can be viewed as hypocritical in my view. His post has surely attracted a large audience, and I am sure he knew it would before he published it. Just like I know this post will surely do the same.
I am not suggesting that his intentions were to generate hype and cause controversy, but he is in the media spotlight, and thus, hype is always good.
Just like how the major news stations cover the Paris Hilton imprisonment saga for ratings, so do bloggers and financial sites with Dendreon.
What do I think of Dendreon? I have never invested in it, and will never touch it. Why? Because I shy away from media hyped stocks, and gravitate towards lesser known healthcare companies, like Heska (HSKA), Opko (OPK), and Lifecell (LIFC) which have made me a lot more money than what Dendreon would have, all without the heart wrenching volatility.
Regardless, I still do believe that cancer vaccines will prove successful in the long run based on preliminary survival data, and so will the companies developing them, whether it is Dendreon, Cell Genesys (CEGE) or Geron (GERN).
Disclosure: Author owns stock in HSKA and LIFC. Dr.Ayoub is not a chartered financial analyst. BioHealth Investor constitutes his own personal opinion and not financial advice. Dr.ayoub nor the site is responsible for any financial loss or damage related to the information in this article. Readers should consult a professional for investment advice.
RRELATED READING:
- Dendreon Deservingly Jumps on New Cancer Vaccine Report
- Options Expiration Weighing on Dendreon
- Cell Genesys Should Not Trade With Dendreon!
List your biotech company on the new BHI Company Directory
_____________
BioHealth Investor.com
My post on Dendreon (DNDN) a couple of days ago attracted a strong response, both critical and approving.
But I am not surprised at the level of hype the article generated; Dendreon has been a gold mine for financial bloggers and sites for the last few months.
Adam Feuerstein and James Altucher can both attest to the large following their Dendreon posts atract. So can 247WallSt, and so can I.
I follow Adam's writing on a regular basis, and find his analysis both accurate and informative. He has a great outlook on the reality of various investment situations in biotech. But his criticism of the media's pumping of Dendreon can be viewed as hypocritical in my view. His post has surely attracted a large audience, and I am sure he knew it would before he published it. Just like I know this post will surely do the same.
I am not suggesting that his intentions were to generate hype and cause controversy, but he is in the media spotlight, and thus, hype is always good.
Just like how the major news stations cover the Paris Hilton imprisonment saga for ratings, so do bloggers and financial sites with Dendreon.
What do I think of Dendreon? I have never invested in it, and will never touch it. Why? Because I shy away from media hyped stocks, and gravitate towards lesser known healthcare companies, like Heska (HSKA), Opko (OPK), and Lifecell (LIFC) which have made me a lot more money than what Dendreon would have, all without the heart wrenching volatility.
Regardless, I still do believe that cancer vaccines will prove successful in the long run based on preliminary survival data, and so will the companies developing them, whether it is Dendreon, Cell Genesys (CEGE) or Geron (GERN).
Disclosure: Author owns stock in HSKA and LIFC. Dr.Ayoub is not a chartered financial analyst. BioHealth Investor constitutes his own personal opinion and not financial advice. Dr.ayoub nor the site is responsible for any financial loss or damage related to the information in this article. Readers should consult a professional for investment advice.
RRELATED READING:
- Dendreon Deservingly Jumps on New Cancer Vaccine Report
- Options Expiration Weighing on Dendreon
- Cell Genesys Should Not Trade With Dendreon!
List your biotech company on the new BHI Company Directory
_____________
posted by Nico at
10:17 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home